Noor Ul Ain Rehman
Tue, March 31, 2026 astatine 10:06 AM CDT 2 min read
In different development, BridgeBio Pharma, Inc. (NASDAQ:BBIO) was initiated with an Outperform standing connected March 10 by William Blair, with a just worth estimation of $93.03 per share. The steadfast told investors successful a probe enactment that the institution is simply a commercial-stage biotech successful a “unique position”, with an accelerating motorboat successful Attruby, regulatory submission for infigratinib successful achondroplasia planned for the 2nd fractional of 2026, and near-term caller cause exertion submissions mounting up late-2026 oregon early-2027 launches. Blair added that it sees Attruby to beryllium good positioned for growth.
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is simply a commercial-stage biopharmaceutical institution that discovers, creates, tests, and delivers transformative medicines to dainty patients suffering from familial diseases and cancers.
While we admit the imaginable of BBIO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich successful 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey connected Google News.

2 days ago
3





English (CA) ·
English (US) ·
Spanish (MX) ·